What's in MyoKardia, Inc.'s pipeline?

MyoKardia, Inc. has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with MyoKardia, Inc.'s portfolio?

Top competitors by shared drug class: Bristol-Myers Squibb.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/myokardia-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

MyoKardia, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MyoKardia, Inc. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Camzyos	MYK-461	marketed	Cardiac Myosin Inhibitor [EPC]	Myosin-7	Cardiovascular	2022-01-01

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2034-06-19 — Camzyos · 9181200 · US
2034-06-19 — Camzyos · 9585883 · US

Competitive overlap (companies sharing drug classes)

Bristol-Myers Squibb · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for MyoKardia, Inc.:

Cite this brief

Drug Landscape (2026). MyoKardia, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/myokardia-inc. Accessed 2026-05-17.